About

SFA Therapeutics, LLC is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment inflammatory diseases. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease (IBD), Crohn's Disease, Psoriasis, Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), and even cancer. Our microbiome-derived drugs are derived from natural substances identified at Temple University, and enable a new platform for developing treatments potentially aimed at over 100 inflammatory diseases currently afflicting patients; with safer treatments than current therapies. Our initial focus is in Psoriasis and Liver Disease (Hepatitis B, NASH and Hepatitis C). Patents have been filed in both of these diseases, based on animal data in Liver Disease and on a small human case-controlled trial ex-US in Psoriasis. Additional patents are expected in a wide range of inflammatory diseases, including an ophthalmic disease, prenatal care and CAR-T (immuno-oncology). The current funding of $50K came from the founder. Our current focus is on raising $1.5M in seed capital to enable demonstration of Proof of Concept (POC) in Psoriasis, and on continuing to build our intellectual property estate. Because these drugs are derived from Generally Regarded As Safe (GRAS) substances they are not expected to require genotoxic testing, and should enable a much faster development path than traditional pharmaceuticals. Our business plan is to develop R&D and licensing partnerships with major pharmaceutical and biotech companies in each key disease indication, and to rapidly develop these into treatments for patients. Payout for these types of deals can return significant multiples on the original investments.